RxDoctor Payments Data

Paul Salva

Pediatric Pulmonology · Springfield, MANPI 1114914363

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 72.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $11,031 and has fallen 95.2% since, to $529 in 2025.

$21,174in general payments, 2019–2025

Across 469 payments — averaging $45.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$15K
  • GSK$1K
  • Sanofi$918
  • Regeneron Healthcare Solutions, Inc.$784
  • Amgen$767
  • Novartis$763
  • plus $1K from 9 others

What the payments were for

  • Speaking & faculty fees$11,40054%
  • Travel & lodging$930%
  • Food & beverage$9,59045%
  • Education$900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,174 in reported general payments places this provider in the 85th percentile of 40 pediatric pulmonology providers in Massachusetts.

See all pediatric pulmonology providers in Massachusetts

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab11$42,053
Azithromycin11$47

Paid to pharmacies, not to this prescriber.

Other pediatric pulmonology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →